Real-world safety and effectiveness of canakinumab in patients with tumour necrosis factor receptor-associated periodic syndrome or hyperimmunoglobulinaemia D syndrome: Interim results from post-marketing surveillance in Japan
Modern Rheumatology · 02.03.2023 · 33 (2) · 381-391
DOI: 10.1093/mr/roac041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Rheumatology, online erschienen am 16.05.2022. Verfasst von Kumiko Hosono und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical Division, Novartis Pharma K.K., Tokyo, Japan. Hauptthemen laut MEDLINE: Mevalonate Kinase Deficiency, Familial Mediterranean Fever. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Pharma.
Abstract (Originalsprache)
Objectives
To assess the real-world safety and effectiveness of canakinumab in patients in Japan with tumour necrosis factor receptor-associated periodic syndrome (TRAPS) or mevalonate kinase deficiency/hyperimmunoglobulinaemia D with periodic fever syndrome (MKD/HIDS).
Methods
All patients with TRAPS or MKD/HIDS who received canakinumab following drug approval in Japan were registered in a post-marketing all-patient surveillance with a 2-year observation period. Herein, the interim results are reported.
Results
Fifteen patients with TRAPS and seven with MKD/HIDS were included in the safety and effectiveness analysis set. Adverse drug reactions were reported in 26.67% (n = 4) and 42.86% (n = 3) of TRAPS and MKD/HIDS patients, respectively. Most common adverse drug reactions were upper respiratory tract inflammation (13.33%, n = 2) and pyrexia (42.86%, n = 3) in TRAPS and MKD/HIDS patients, respectively. No serious adverse drug reactions were observed in either TRAPS or MKD/HIDS patients. The proportion of responders was 46.67% and 14.29% in the TRAPS and MKD/HIDS groups, respectively; 72.73% and 66.67% achieved clinical remission, while 90.91% and 66.67% achieved serological remission by Week 4 in the TRAPS and MKD/HIDS groups, respectively.
Conclusions
These interim results provide the first evidence of the real-world effectiveness of canakinumab in patients with TRAPS or MKD/HIDS in Japan. No new safety concerns were identified.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Division, Novartis Pharma K.K., Tokyo, Japan.
- Clinical Development & Analytics Japan Integrated Biostatistics Japan Biostatistics Pharma, Novartis Pharma K.K., Tokyo, Japan.
- Clinical Development & Analytics Japan CDD and Re-examination CDD2, Novartis Pharma K.K., Tokyo, Japan.
Förderung
- Novartis Pharma
Zitieren
APA
Hosono, K., Matsumoto, K., Shimbo, M., Tsumiyama, I., & Kato, C. (2023). Real-world safety and effectiveness of canakinumab in patients with tumour necrosis factor receptor-associated periodic syndrome or hyperimmunoglobulinaemia D syndrome: Interim results from post-marketing surveillance in Japan. Modern Rheumatology, 33(2), 381-391. https://doi.org/10.1093/mr/roac041
Vancouver
Hosono K, Matsumoto K, Shimbo M, Tsumiyama I, Kato C. Real-world safety and effectiveness of canakinumab in patients with tumour necrosis factor receptor-associated periodic syndrome or hyperimmunoglobulinaemia D syndrome: Interim results from post-marketing surveillance in Japan. Modern Rheumatology. 2023;33(2):381-391. doi:10.1093/mr/roac041
BibTeX
@article{Hosono2023,
author = {Hosono, Kumiko and Matsumoto, Kazuko and Shimbo, Miki and Tsumiyama, Isao and Kato, Chihiro},
title = {Real-world safety and effectiveness of canakinumab in patients with tumour necrosis factor receptor-associated periodic syndrome or hyperimmunoglobulinaemia D syndrome: Interim results from post-marketing surveillance in Japan},
journal = {Modern Rheumatology},
year = {2023},
volume = {33},
number = {2},
pages = {381--391},
doi = {10.1093/mr/roac041}
}
EUVIMED